An EORTC phase I study of capecitabine (Xeloda®) in combination with fixed doses of cyclophosphamide and epirubicin (CEX) as primary treatment for large operable or locally advanced/inflammatory breast cancer

Nom du journal : Eur J Cancer

Année : 2003

Volume : 39

Page de départ : 1277

Page de fin : 1283

Auteurs: Bonnefoi H, Biganzoli L, Mauriac L, Cufer T, Schaefer P, Atalay G, Piccart M, Atalay G,